ES2573253T3 - Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor - Google Patents

Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor Download PDF

Info

Publication number
ES2573253T3
ES2573253T3 ES07842927.1T ES07842927T ES2573253T3 ES 2573253 T3 ES2573253 T3 ES 2573253T3 ES 07842927 T ES07842927 T ES 07842927T ES 2573253 T3 ES2573253 T3 ES 2573253T3
Authority
ES
Spain
Prior art keywords
supply
methods
pain relief
regional anesthesia
isoflurane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07842927.1T
Other languages
English (en)
Inventor
Phillip C. Phan
Allen W. Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2573253T3 publication Critical patent/ES2573253T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un anestésico de éter halogenado disuelto en una preparación farmacéutica para uso en un método para reducir el dolor en un sujeto en necesidad de dicha reducción del dolor, el método comprende administrar dicha preparación farmacéutica tópicamente en una cantidad efectiva para reducir el dolor, en donde dicho anestésico es isoflurano, y en donde dicho sujeto es un humano o en donde dicho sujeto es un ratón o una rata.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
CONTROL
5 MIN 10 MIN 15 MIN 30 MIN 60 MIN
RATA 1
4.8 11 5.4 7.6 6.8 6.1
4.4
15 9 7.3 7.2 5.8.
4.8
19.5 9 8.8 4.9 5.1
20
6.8 7 5.2 4.9
RATA 2
3.4 10.9 9.9 10.4 8.2 3.8
4.3
12.6 8.7 9.4 6.9 4.7
3.6
18.1 12 5.4 8.1 7
17.3
9 13.4 6.4 4.1
RATA 3
3.6 14.2 12.2 6.1 5.2 4.2
3.8
20 12 7.1 6.1 3.5
4.7
20 9.1 4.8 5.8 3.3
16
8.9 5.2 6.5 3.8
RATA 5
3.9 9.8 8.8 7.9 4.9 4.2
2.6
11.8 7.8 6.4 4.3 3.5
2.6
9.1 10.2 6.9 4.7 3.8
11.8
8.1 4.3 3.8 3.5
media
3.875 14.81875 9.18125 7.375 5.9375 4.45625
DE
0.767671 3.809235 1.77067 2.231171 1.266331 1.073293
Ejemplo III (ejemplo de referencia)
Inhibición intratecal del dolor utilizando isoflurano disuelto en fluido cerebroespinal artificial
Se mide la sensibilidad al dolor después de la administración intratecal de isoflurano en fluido cerebroespinal artificial
5 (ACSF). Adicionalmente, como se detalla adelante, el isoflurano primero se disuelve en ACSF y luego se somete a sonicación antes de la administración. La relación de respuesta de dosis luego se evalúa al generar una gráfica de estímulo-respuesta (SR) con el propósito de determinar concentraciones relevantes de isoflurano que se pueden administrar intratecalmente para lograr analgesia o anestesia. La caracterización del perfil farmacológico de la administración intratecal de isoflurano in ACSF se realiza en este ejemplo utilizando ratas; adicionalmente, como lo
10 apreciaría un experto en la técnica, se pueden utilizar métodos análogos para determinar el perfil farmacológico preciso en humanos.
Se prepara isoflurano disuelto en ACSF mediante el siguiente método. Se mezcla isoflurano en un recipiente vacío cerrado en una relación v/v de 10-50% con solución de sal regulada que aproxima fluido cerebroespinal (pH 7.4) con la siguiente composición (en mM): NaCl, 120; KCl, 3; NaHCO3. 25; CaCl2, 2.5; MgCl2, 0.5; glucosa, 12. Las
15 soluciones combinadas se agitan mecánicamente durante 3-5 min y luego se mantienen en un sonicador termoneutro hasta uso.
12
imagen11
Sorkin et al., Anesthesiology, 95:965-973, 2001. Takenoshita et al., Progress in Anesthetic Mechanism, 3(1994): 326-329,1995 Yaksh et al., J. Appl. Physiol., 90:2386-2402, 2001.
14

Claims (1)

  1. imagen1
    imagen2
ES07842927.1T 2006-09-20 2007-09-20 Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor Active ES2573253T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84629306P 2006-09-20 2006-09-20
US846293P 2006-09-20
US94721907P 2007-06-29 2007-06-29
US947219P 2007-06-29
PCT/US2007/079097 WO2008036858A2 (en) 2006-09-20 2007-09-20 Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief

Publications (1)

Publication Number Publication Date
ES2573253T3 true ES2573253T3 (es) 2016-06-06

Family

ID=39092912

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07842927.1T Active ES2573253T3 (es) 2006-09-20 2007-09-20 Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor

Country Status (9)

Country Link
US (3) US20080119820A1 (es)
EP (1) EP2081562B1 (es)
JP (4) JP2010504359A (es)
AU (1) AU2007299738B2 (es)
CA (1) CA2663857C (es)
DK (1) DK2081562T3 (es)
ES (1) ES2573253T3 (es)
PL (1) PL2081562T3 (es)
WO (1) WO2008036858A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2721701B2 (ja) 1989-04-20 1998-03-04 株式会社千代田製作所 有機溶剤を使用する洗浄装置の運転方法
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
PL2244737T3 (pl) 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
EP2244783B1 (en) 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
WO2010025505A1 (en) * 2008-09-04 2010-03-11 Phebra Pty Ltd Analgesia by transmucosal administration
CN109394689A (zh) 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
DE102010042615A1 (de) * 2010-10-19 2012-04-19 Wacker Chemie Ag 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel
EP2723325A4 (en) 2011-06-24 2015-03-11 Vapogenix Inc NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
PL2968214T3 (pl) 2013-03-15 2021-11-02 Newvapogen, Inc. Nowe kompozycje przeciwbólowe
US20150321770A1 (en) * 2014-03-09 2015-11-12 Davy Zide Qian New method to prevent or stop an airplane from being hijacked and to minimize the effect of damage by using remote and wireless real-time monitoring and inhalational general anesthetic gases controlled from the ground (level)
CN104841025B (zh) * 2015-04-16 2017-10-24 河南科技大学第一附属医院 一种用于密闭腰椎穿刺及脑脊液置换的装置
WO2017011865A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
WO2017011867A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
EP3325062A4 (en) 2015-07-20 2019-03-13 Medical Developments International Limited INHALER FOR INHALABLE LIQUIDS
AU2017325107B2 (en) 2016-09-06 2022-10-06 Medical Developments International Limited Inhaler device for inhalable liquids
CN110141508A (zh) * 2019-05-20 2019-08-20 崔文馨 无菌净化空气生理盐水
EP4522112A1 (en) 2022-05-13 2025-03-19 Laboratorios Gebro Pharma, S.A. Pharmaceutical composition for topical administration comprising a volatile anaesthetic

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786675A (fr) * 1971-08-02 1973-01-25 Airco Inc Separation d'oxydes d'alkyle halogenes par distillation azeotropique.
US4109651A (en) * 1975-11-19 1978-08-29 Steigerwald Allan M Anesthetic gas exhaust system
US4453951A (en) * 1980-07-09 1984-06-12 General Electric Co. Process for the production of silicone carbide composite
SE8008962L (sv) * 1980-12-18 1982-06-19 Erik Allan Lindkvist Anordning vid narkosmask
US4879062A (en) 1981-10-20 1989-11-07 Adamantech, Inc. Preparation of a gel having gas transporting capability
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
DE4105972C2 (de) * 1991-02-26 1999-06-02 Draegerwerk Ag Narkosemitteldosiervorrichtung
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US5230778A (en) * 1992-05-01 1993-07-27 Gavlin Associates Purification of isoflurane by extractive distillation
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9308306D0 (en) * 1993-04-22 1993-06-09 Univ Aberdeen Analgesic composition
PT711289E (pt) * 1993-07-30 2001-02-28 Delta Pharmaceuticals Inc Compostos piperazina utilizados em terapia
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
US5568910A (en) * 1995-03-02 1996-10-29 Delmarva Laboratories, Inc. Anesthesia machine
US6248788B1 (en) * 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
CA2288828A1 (en) 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US5976072A (en) * 1998-01-29 1999-11-02 Johns Hopkins University Copa method for fiberoptic endotracheal intubation
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6830581B2 (en) * 1999-02-09 2004-12-14 Innercool Therspies, Inc. Method and device for patient temperature control employing optimized rewarming
US6869440B2 (en) * 1999-02-09 2005-03-22 Innercool Therapies, Inc. Method and apparatus for patient temperature control employing administration of anti-shivering agents
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
US6653354B2 (en) * 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
US6706034B1 (en) * 1999-12-30 2004-03-16 Advanced Cardiovascular Systems, Inc. Process for agent retention in biological tissues
US6669954B2 (en) * 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
AU2001254625B2 (en) 2000-05-02 2006-02-02 Action Pharma A/S Use of alpha-MSH and EPO for preventing or treating ischemic conditions
US6770636B2 (en) * 2000-08-18 2004-08-03 Boehringer Ingelheim Pharma Kg Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
MXPA04006572A (es) 2002-01-10 2005-11-04 Upjohn Co Terapia de combinacion antivirica.
US20030181426A1 (en) * 2002-02-11 2003-09-25 Eisenach James C. Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
AU2003219167A1 (en) 2002-03-19 2003-09-29 Genset Sa Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists
ES2346868T3 (es) 2002-08-10 2010-10-21 Yale University Antagonistas de receptor nogo.
CA2500310C (en) * 2002-10-11 2013-03-12 Baxter International, Inc. Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
NZ542690A (en) 2003-03-28 2009-04-30 Acadia Pharm Inc Muscarinic M1 receptor agonists for pain management
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US20030173287A1 (en) * 2003-05-06 2003-09-18 Johnston Arthur W Filter devices and methods of use
EP1631234B1 (en) 2003-05-16 2011-09-14 Acorda Therapeutics, Inc. Compositions and methods for the treatment of cns injuries
BRPI0413426A (pt) 2003-08-07 2006-10-17 Biogen Idec Inc antagonistas de receptor novo
ATE395052T1 (de) 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
DE602004015142D1 (de) 2003-08-29 2008-08-28 Childrens Medical Center Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
KR20060088885A (ko) 2003-09-25 2006-08-07 아카디아 파마슈티칼스 인코포레이티드 뉴로펩티드 ｆｆ 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2006064886A1 (ja) 2004-12-16 2006-06-22 Anges Mg, Inc. 骨形成調節剤
WO2006088088A1 (ja) 2005-02-16 2006-08-24 Astellas Pharma Inc. Ｒｏｃｋ阻害剤を含有する疼痛治療剤
EP2099408B1 (en) 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
PL2244737T3 (pl) 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
EP2244783B1 (en) 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
CN109394689A (zh) 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法

Also Published As

Publication number Publication date
US10357464B2 (en) 2019-07-23
JP5827658B2 (ja) 2015-12-02
EP2081562A2 (en) 2009-07-29
JP2016041721A (ja) 2016-03-31
JP2014074028A (ja) 2014-04-24
DK2081562T3 (en) 2016-05-30
AU2007299738B2 (en) 2013-03-28
US20190358173A1 (en) 2019-11-28
CA2663857C (en) 2017-10-31
US20080119820A1 (en) 2008-05-22
JP6312146B2 (ja) 2018-04-18
EP2081562B1 (en) 2016-02-24
JP2010504359A (ja) 2010-02-12
CA2663857A1 (en) 2008-03-27
WO2008036858A3 (en) 2008-08-07
AU2007299738A1 (en) 2008-03-27
US10799466B2 (en) 2020-10-13
JP2017218450A (ja) 2017-12-14
WO2008036858A2 (en) 2008-03-27
US20110269843A1 (en) 2011-11-03
PL2081562T3 (pl) 2017-05-31

Similar Documents

Publication Publication Date Title
ES2573253T3 (es) Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor
Cundy et al. XP13512 [(±)-1-([(α-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys
BR112020023452A2 (pt) composições de agonista de gip/glp1
AR052198A1 (es) Formulaciones anticuerpo anti a beta
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
AR063782A1 (es) Parche y metodo transdermico para emesis
US20220387445A1 (en) Prostacyclin analogue formulations
Liu et al. Novel EP4 receptor agonist‐bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss
Brigham et al. Pharmacokinetic/pharmacodynamic correlation analysis of amantadine for levodopa-induced dyskinesia
US20040048900A1 (en) Nicotine and/or nicotine agonists for the treatment of general anesthetic effects and side effects
RS53804A (sr) Parenteralna kompozicija paracetamola
KR102923666B1 (ko) 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법
CN102196819A (zh) 局部麻醉用组合物
RU2009102803A (ru) Пригодный для инъекции состав антибиотика и раствор для его внутреннего введения
Wang et al. Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage
Larenza et al. Stereoselective pharmacokinetics of ketamine and norketamine after constant rate infusion of a subanesthetic dose of racemic ketamine or S-ketamine in Shetland ponies
Diao et al. Comparison of the effects of propofol and emulsified isoflurane alone or combined with dexmedetomidine on induction of anesthesia in dogs
López-Arnau et al. The combination of MDPV and ethanol results in decreased cathinone and increased alcohol levels. Study of such pharmacological interaction
BR112017016010B1 (pt) Preparação aquosa para uso externo.
ES2726401T3 (es) Uso de inhibidores de HDAC para el tratamiento de la destrucción ósea
BRPI0506710A (pt) composições farmacêuticas de liberação controlada
TWI544924B (zh) 經皮吸收製劑
BR112017012975B1 (pt) Formulações injetáveis de paracetamol
Li et al. Post-training intra-basolateral amygdala infusions of norepinephrine block sevoflurane-induced impairment of memory consolidation and activity-regulated cytoskeletal protein expression inhibition in rat hippocampus
DE102006016990A1 (de) Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen